Johnson & Johnson (JNJ)

Executive Summary

Johnson & Johnson is a global healthcare leader operating through two segments: Innovative Medicine and MedTech. The 2023 spin-off of Kenvue sharpened its focus on high-growth prescription drugs and medical devices. With a robust pipeline of over 700 candidates, including promising therapies in oncology, immunology, and neuroscience, J&J is positioned to drive long-term growth. Its strong balance sheet and consistent dividend provide stability, though patent expirations and talc litigation remain headwinds. Overall, J&J offers a resilient business model with moderate growth prospects.

Upcoming Catalysts (preview)

• Q3 2026Nipocalimab FDA approval for generalized myasthenia gravis80% success
• Q4 2026Talquetamab label expansion in relapsed/refractory multiple myeloma70% success
• H2 2026Resolution of talc-related litigation via proposed settlement50% success